Bank of America believes Alvotech could be approaching a major turning point as regulatory pressure eases and several biosimilar launches move closer to the market. Alvotech enters a new phase Alvotech has spent years developing its biosimilar business while dealing with regulatory delays, manufacturing expenses and inconsistent commercial results. Now, Bank of America believes those […]

The postBank of America sees major upside in this biotech stockappeared first onRolling Out.